Helixr Perspective #25

Restructuring in Life Sciences: What the headcount numbers don't tell you

Restructuring in life sciences

Share:

Related solution

Business transformation

We provide and deliver solutions to meet your goals. On time. On budget.
The restructuring headlines in life sciences over the past two years have been hard to miss. Novo Nordisk announced approximately 9,000 job cuts in 2025. Merck has conducted multiple rounds of layoffs, including at its Rahway headquarters, as part of a $3 billion cost-saving programme running through 2027. Bayer has significantly reduced its workforce under its ongoing restructuring programme, with more than 12,000 positions eliminated since 2023. These announcements reflect a broader trend of restructuring and cost-reduction initiatives across the pharmaceutical and life sciences sector.

The commentary around each of these has followed a familiar pattern: headcount numbers, cost savings targets, market reaction. What gets far less attention is the harder question underneath: what happens to the operational capability, the institutional knowledge, and the process infrastructure that restructuring inevitably disrupts; and what does that cost the organisation over the following two or three years, long after the announcement has stopped making headlines.

The gap between the cost case and the capability case

Restructuring decisions in life sciences are, understandably, built around a financial case. Cost per employee, projected savings, timeline to realisation. These numbers are necessary and they are usually rigorous. What is far less consistently rigorous is the parallel assessment of what capability actually leaves the organisation when a restructuring programme is executed; and whether that capability can be rebuilt, replaced, or simply lived without.

This matters more in life sciences than in almost any other sector. The knowledge that sits with an experienced regulatory affairs specialist, a quality assurance lead who understands exactly why a process is designed the way it is, a manufacturing expert who has navigated three previous technology transfers – this knowledge is not well documented, because much of it cannot be. It exists in judgement, in pattern recognition, in the accumulated experience of having seen what goes wrong and why. When that knowledge leaves in a restructuring programme, it does not show up as a line item anywhere. It shows up, months later, as a compliance issue that should have been anticipated, a technology transfer that takes twice as long as planned, a process deviation that a more experienced eye would have caught before it became a problem.

The compounding effect in a regulated industry

Restructuring risk is not evenly distributed across industries, and life sciences carries more of it than most. The regulatory and compliance burden that defines the sector means that institutional knowledge is not simply useful, it is often the mechanism by which compliance is actually maintained day to day, in ways that formal documentation only partially captures.

Add to this the current operating environment. Nearly half of life sciences executives now cite accelerated digital transformation as a major factor shaping their organisations in 2026. Over a third are managing agency restructuring within the FDA and HHS. A similar proportion are navigating new tariff and trade policy. Regulatory change is intensifying, not easing, in most major markets simultaneously.

Restructuring programmes are landing directly on top of this complexity, often justified, at least in part, by the need to fund the digital and AI transformation that the same executives cite as their top strategic priority. The result is an environment where organisations are removing experienced capability and increasing operational complexity at the same time, and treating these as separate decisions rather than a single, compounding risk.

What tends to get missed

A few patterns show up consistently in restructuring programmes that later run into difficulty.

The org chart is treated as the map of where knowledge sits. It rarely is. Institutional knowledge does not respect reporting lines, it accumulates in specific individuals, often not the most senior people in a function, who have simply been present for enough history to understand why things work the way they do. Restructuring decisions made purely on the basis of role, level, or cost per head can remove this knowledge without anyone involved in the decision realising what has been lost until much later.

Process ownership becomes unclear. When restructuring removes people faster than processes are redesigned to function without them, the result is not fewer people doing the same work more efficiently. It is the same work, with gaps, being managed reactively by whoever is left. This is where the handoff failures we’ve written about previously tend to intensify – the connective tissue between functions is disproportionately affected, because it was rarely explicitly owned in the first place.

The knowledge transfer window is treated as an afterthought. When departures are announced with short notice, as they often are, for understandable commercial and legal reasons, there is frequently no structured mechanism for capturing what the departing individual actually knows before they leave. What could have been a deliberate, prioritised handover becomes an informal, incomplete one, if it happens at all.

What better restructuring looks like

None of this is an argument against restructuring. Cost discipline is a legitimate and often necessary response to the pressures the life sciences sector is currently navigating. The argument is for restructuring that accounts for capability risk with the same rigour it applies to cost, because the organisations that do this consistently recover faster and retain more value from the transition.

This means mapping institutional knowledge before restructuring decisions are finalised; not as a formality, but as a genuine input into which roles carry disproportionate risk if removed. It means building structured knowledge transfer into every departure with meaningful notice, rather than treating it as optional. It means being deliberate about process ownership during and after the transition, so that the gaps left by departing roles are consciously redesigned around rather than silently absorbed by whoever remains.

And it means being honest, at the point the restructuring case is built, about the difference between headcount cost and capability cost. These are not the same number, and treating them as though they are is how organisations end up spending, eighteen months later, considerably more than they saved – in remediation, in rework, in the slow rebuilding of judgement that took years to develop the first time.

The real cost of moving fast without looking down

Life sciences organisations are under genuine, legitimate pressure to restructure in 2026 – pipeline economics, tariff exposure, the cost of AI and digital investment, shareholder expectations, all of it real. The pressure to move quickly is understandable.

But speed and care are not opposites here. The organisations that will look back on this period as having navigated it well are not the ones that avoided restructuring. They are the ones that restructured with a clear-eyed understanding of what they were actually giving up, and made deliberate decisions, rather than discovering the cost by accident, further down the road.

Helixr works with life sciences organisations navigating restructuring, integration, and transformation, helping protect the operational capability and institutional knowledge that programmes depend on. If your organisation is planning or managing a restructuring programme, please contact us.

Connect with Helixr
Let’s have a conversation. Contact us to find out more about what we can do for you.